Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Silo Pharma ( (SILO) ) has issued an announcement.
On October 1, 2025, Silo Pharma closed a securities purchase agreement with institutional investors, selling 2,857,143 shares of common stock at $0.875 per share, raising approximately $2.5 million. The company issued unregistered warrants for additional shares, with proceeds intended for working capital and general corporate purposes. The engagement with H.C. Wainwright & Co. as the exclusive placement agent involved fees and warrants for the agent. This move is part of Silo Pharma’s strategy to strengthen its financial position and support its developmental programs.
More about Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The company focuses on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its portfolio includes programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo Pharma collaborates with leading universities and laboratories for its research.
Average Trading Volume: 1,285,951
Technical Sentiment Signal: Sell
Current Market Cap: $7.09M
For a thorough assessment of SILO stock, go to TipRanks’ Stock Analysis page.